Changes in Hong Kong stocks | Heplatinum Pharmaceutical-B (02142) rose nearly 5% in early trading and the subsidiary Nona Biotech successfully developed a HcaBlm training language model

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose nearly 5% in early trading. As of press release, it had risen 4.02% to HK$12.94, with a turnover of HK$10,818,900.

According to the news, on September 16, Heplatinum Pharmaceutical-B announced that Nona Biotech (Nona), a wholly-owned subsidiary of the company, has successfully developed hCaBlm — the world's first language model based on wholly human-derived heavy chain antibodies (HCABs) training. The related research paper “A Foundation Model Approaches the Sequence and Functional Grammar of Fully Human Heavy-Chain-Only Combinations” has been published on bioRXiv.

Based on a large-scale database of 31.8 million all-human HCaB sequences from 73 independently immunized HCaB transgenic mice, hcaBLM aims to capture the unique sequence characteristics of all human HCaB. The development of hCaBlm marks an important advance in Nona's application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody libraries with AI-driven modeling, Nona is laying the foundation for more efficient, data-driven antibody design and developability assessments.